Single User License
INR 135120
Site License
INR 270240
Corporate User License
INR 405360

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Fatty Liver Disease-Pipeline Review, H1 2015

Fatty Liver Disease-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Fatty Liver Disease-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Fatty Liver Disease-Pipeline Review, H1 2015', provides an overview of the Fatty Liver Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Fatty Liver Disease Overview 10

Therapeutics Development 11

Pipeline Products for Fatty Liver Disease-Overview 11

Pipeline Products for Fatty Liver Disease-Comparative Analysis 12

Fatty Liver Disease-Therapeutics under Development by Companies 13

Fatty Liver Disease-Therapeutics under Investigation by Universities/Institutes 16

Fatty Liver Disease-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Fatty Liver Disease-Products under Development by Companies 21

Fatty Liver Disease-Products under Investigation by Universities/Institutes 23

Fatty Liver Disease-Companies Involved in Therapeutics Development 24

ACROVIS biostructures GmbH 24

ChemoCentryx, Inc. 25

Conatus Pharmaceuticals Inc. 26

Daewoong Pharmaceutical Co., Ltd. 27

Dr. Falk Pharma GmbH 28

DURECT Corporation 29

Galmed International Ltd. 30

Generon (Shanghai) Corporation Ltd. 31

Genovate Biotechnology Co., LTD. 32

Gilead Sciences, Inc. 33

Huons Co., Ltd. 34

Kyorin Pharmaceutical Co., Ltd. 35

Metabolic Solutions Development Company, LLC 36

Novartis AG 37

Protalix BioTherapeutics, Inc. 38

Raptor Pharmaceuticals Corp. 39

TCM Biotech International Corp 40

Tobira Therapeutics, Inc. 41

Verva Pharmaceuticals Limited 42

Zafgen Inc. 43

Fatty Liver Disease-Therapeutics Assessment 44

Assessment by Monotherapy Products 44

Assessment by Target 45

Assessment by Mechanism of Action 48

Assessment by Route of Administration 50

Assessment by Molecule Type 51

Drug Profiles 53

ACR-488-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Aramchol-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

CCX-872-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

cenicriviroc mesylate-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

CSN-501-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

cysteamine DR-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

DV-928-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

DWP-10292-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

emricasan-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

etanercept biosimilar-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

F-652-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

HU-002-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

MAT-8800-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

MB-12066-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

methazolamide-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

MN-002-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

MSDC-0602-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

norursodeoxycholic acid-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

oltipraz-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

PCBB-7-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

pradigastat sodium-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Px-102-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

Px-103-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Px-104-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Recombinant Protein for Atherosclerosis and Hepatic Steatosis-Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

Small Molecule to Inhibit Them1 for Metabolic, Immunology and Gastrointestinal Diseases-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Small Molecules to Activate AMPK for Fatty Liver Disease-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

SR-9238-Drug Profile 89

Product Description 89

Mechanism of Action 89

R&D Progress 89

Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

TCM-606F-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

VVP-100-X-Drug Profile 93

Product Description 93

Mechanism of Action 93

R&D Progress 93

ZGN-839-Drug Profile 94

Product Description 94

Mechanism of Action 94

R&D Progress 94

Fatty Liver Disease-Recent Pipeline Updates 95

Fatty Liver Disease-Dormant Projects 112

Fatty Liver Disease-Product Development Milestones 114

Featured News & Press Releases 114

Jan 12, 2015: Researchers uncover more clues to how drug reverses obesity, diabetes, fatty liver disease 114

Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 115

Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies 116

Mar 03, 2014: Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial 116

Dec 19, 2012: Scripps Florida Scientists Develop New Compound that Reverses Fatty Liver Disease 117

Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102 118

Oct 06, 2011: Metabolic Solutions Development Company Receives $1.1m NIH Grant To Further Investigate MSDC-0602 For Treatment Of Fatty Liver Disease 119

Oct 14, 2010: Galmed Initiates Phase II Clinical Trial Of Aramchol For Treatment Of Fatty Liver Disease 119

Sep 21, 2008: Galmed Medical Research Initiates Its Phase I study Of Aramchol, Its Drug Candidate For Fatty Liver Disease 120

Appendix 122

Methodology 122

Coverage 122

Secondary Research 122

Primary Research 122

Expert Panel Validation 122

Contact Us 122

Disclaimer 123

List of Tables

Number of Products under Development for Fatty Liver Disease, H1 2015 11

Number of Products under Development for Fatty Liver Disease-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 14

Number of Products under Development by Companies, H1 2015 (Contd..1) 15

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Late Stage Development, H1 2015 17

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Development, H1 2015 19

Comparative Analysis by Unknown Stage Development, H1 2015 20

Products under Development by Companies, H1 2015 21

Products under Development by Companies, H1 2015 (Contd..1) 22

Products under Investigation by Universities/Institutes, H1 2015 23

Fatty Liver Disease-Pipeline by ACROVIS biostructures GmbH, H1 2015 24

Fatty Liver Disease-Pipeline by ChemoCentryx, Inc., H1 2015 25

Fatty Liver Disease-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 26

Fatty Liver Disease-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 27

Fatty Liver Disease-Pipeline by Dr. Falk Pharma GmbH, H1 2015 28

Fatty Liver Disease-Pipeline by DURECT Corporation, H1 2015 29

Fatty Liver Disease-Pipeline by Galmed International Ltd., H1 2015 30

Fatty Liver Disease-Pipeline by Generon (Shanghai) Corporation Ltd., H1 2015 31

Fatty Liver Disease-Pipeline by Genovate Biotechnology Co., LTD., H1 2015 32

Fatty Liver Disease-Pipeline by Gilead Sciences, Inc., H1 2015 33

Fatty Liver Disease-Pipeline by Huons Co., Ltd., H1 2015 34

Fatty Liver Disease-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 35

Fatty Liver Disease-Pipeline by Metabolic Solutions Development Company, LLC, H1 2015 36

Fatty Liver Disease-Pipeline by Novartis AG, H1 2015 37

Fatty Liver Disease-Pipeline by Protalix BioTherapeutics, Inc., H1 2015 38

Fatty Liver Disease-Pipeline by Raptor Pharmaceuticals Corp., H1 2015 39

Fatty Liver Disease-Pipeline by TCM Biotech International Corp, H1 2015 40

Fatty Liver Disease-Pipeline by Tobira Therapeutics, Inc., H1 2015 41

Fatty Liver Disease-Pipeline by Verva Pharmaceuticals Limited, H1 2015 42

Fatty Liver Disease-Pipeline by Zafgen Inc., H1 2015 43

Assessment by Monotherapy Products, H1 2015 44

Number of Products by Stage and Target, H1 2015 47

Number of Products by Stage and Mechanism of Action, H1 2015 49

Number of Products by Stage and Route of Administration, H1 2015 50

Number of Products by Stage and Molecule Type, H1 2015 52

Fatty Liver Disease Therapeutics-Recent Pipeline Updates, H1 2015 95

Fatty Liver Disease-Dormant Projects, H1 2015 112

Fatty Liver Disease-Dormant Projects (Contd..1), H1 2015 113

List of Figures

Number of Products under Development for Fatty Liver Disease, H1 2015 11

Number of Products under Development for Fatty Liver Disease-Comparative Analysis, H1 2015 12

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 16

Comparative Analysis by Clinical Stage Development, H1 2015 18

Comparative Analysis by Early Stage Products, H1 2015 19

Assessment by Monotherapy Products, H1 2015 44

Number of Products by Top 10 Targets, H1 2015 45

Number of Products by Stage and Top 10 Targets, H1 2015 46

Number of Products by Top 10 Mechanism of Actions, H1 2015 48

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 48

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 50

Number of Products by Top 10 Molecule Types, H1 2015 51

Number of Products by Stage and Top 10 Molecule Types, H1 2015 52

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ACROVIS biostructures GmbH

ChemoCentryx, Inc.

Conatus Pharmaceuticals Inc.

Daewoong Pharmaceutical Co., Ltd.

Dr. Falk Pharma GmbH

DURECT Corporation

Galmed International Ltd.

Generon (Shanghai) Corporation Ltd.

Genovate Biotechnology Co., LTD.

Gilead Sciences, Inc.

Huons Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Metabolic Solutions Development Company, LLC

Novartis AG

Protalix BioTherapeutics, Inc.

Raptor Pharmaceuticals Corp.

TCM Biotech International Corp

Tobira Therapeutics, Inc.

Verva Pharmaceuticals Limited

Zafgen Inc.

Fatty Liver Disease Therapeutic Products under Development, Key Players in Fatty Liver Disease Therapeutics, Fatty Liver Disease Pipeline Overview, Fatty Liver Disease Pipeline, Fatty Liver Disease Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com